Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital in San Diego, shared the implications of the findings from INTEGUMENT-PED, the phase 3 study assessing the efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients with atopic dermatitis (AD), for future clinical practice.
This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology.
At the 2024 American Academy of Dermatology Annual Meeting, Lawrence Eichenfield, MD, chief of pediatric dermatology at Rady Children's Hospital in San Diego and professor of dermatology and pediatrics at the University of California, San Diego, presented late-breaking findings from the INTEGUMENT-PED phase 3 randomized controlled trial of roflumilast cream 0.05% in children 2 to 5 years of age with atopic dermatitis (AD).
In an interview with AJMC, Eichenfield said that roflumilast cream 0.05% had positive results in pediatric patients with AD in terms of efficacy and safety. He noted that he is looking forward to roflumilast cream being "hopefully approved" and "potentially having this in our armamentarium for treating young children."
Transcript
How do the results of the INTEGUMENT-PED study contribute to our understanding of AD treatment options for young children? What implications might they have for clinical practice and future research?
First, to go through some of the basics, the study hit the sort of standard outcome measures that we look for. What percentage of patients made it to clear or almost cleared? About 25% of those were within a 4-week time period with once-a-day application with a big delta, or almost 15% delta, between the vehicle.
It was very interesting to me that a lot of the population that got that clear, or almost clear, were already clear or almost clear by 2 weeks, and there was almost 80 something percent of those because it was 21% of the patients made clear or almost clear at week 2.
The secondary outcome measures being clear or almost clear at EASI [Eczema Area and Severity Index] 75, and the percentage of patients who had at least a 4-part drop in itch as compared to their baseline was consistent with a nice separation from the vehicle cream throughout the course of the study.
When we looked very early, the improvement in the itch with roflumilast was seen as early as 24 hours after the first application. So, it was a very rapid separation of itch scores from the vehicle.
Overall, I think having this move forward and hopefully be approved as a new nonsteroidal, which is very well formulated, can be helpful in our care of patients with atopic dermatitis. We show in this case that it helped to improve eczema in 2- to 5-year-olds with early clinical responses and very good tolerance levels. So, we look forward to potentially having this in our armamentarium for treating young children.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
T-Cell Exhaustion in CLL: Allogeneic CAR T Trial Reaching Patients With Unmet Need
April 30th 2024"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges. This article will appear in the May 2024 issue of Evidence-Based Oncology.
Read More